# Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

> **NCT00028496** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Adenocarcinoma of the Colon
- Adenocarcinoma of the Gallbladder
- Adenocarcinoma of the Pancreas
- Adenocarcinoma of the Rectum
- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Cholangiocarcinoma of the Gallbladder
- Diffuse Adenocarcinoma of the Stomach
- Intestinal Adenocarcinoma of the Stomach
- Male Breast Cancer
- Mixed Adenocarcinoma of the Stomach
- Ovarian Endometrioid Adenocarcinoma
- Paget Disease of the Breast With Intraductal Carcinoma
- Paget Disease of the Breast With Invasive Ductal Carcinoma
- Recurrent Adult Primary Liver Cancer
- Recurrent Breast Cancer
- Recurrent Colon Cancer
- Recurrent Gallbladder Cancer
- Recurrent Gastric Cancer
- Recurrent Malignant Testicular Germ Cell Tumor
- Recurrent Pancreatic Cancer
- Recurrent Rectal Cancer
- Recurrent Salivary Gland Cancer
- Salivary Gland Adenocarcinoma
- Stage II Malignant Testicular Germ Cell Tumor
- Stage II Pancreatic Cancer
- Stage III Colon Cancer
- Stage III Gastric Cancer
- Stage III Malignant Testicular Germ Cell Tumor
- Stage III Pancreatic Cancer
- Stage III Rectal Cancer
- Stage III Salivary Gland Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IV Breast Cancer
- Stage IV Colon Cancer
- Stage IV Gastric Cancer
- Stage IV Pancreatic Cancer
- Stage IV Rectal Cancer
- Stage IV Salivary Gland Cancer
- Thyroid Gland Medullary Carcinoma
- Unresectable Gallbladder Cancer

## Interventions

- **BIOLOGICAL:** recombinant fowlpox-CEA(6D)/TRICOM vaccine
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** recombinant fowlpox GM-CSF vaccine adjuvant

## Key facts

- **NCT ID:** NCT00028496
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2005-11
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028496, "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00028496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*